{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T11:10:16Z","timestamp":1795173016009,"version":"4.10.3"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T00:00:00Z","timestamp":1747958400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004089","name":"Krembil Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004089","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Schroeder Arthritis Institute"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,9,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To evaluate change in body weight with DMARDs in PsA.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analysed data from a large cohort of PsA patients with at least two weight measurements over follow-up. The absolute weight difference at one year from drug initiation was evaluated across\u2014no medications or NSAIDs, conventional synthetic (cs) DMARDs, tumour necrosis factor inhibitors (TNFi), IL-12\/23 inhibitor (i), IL-17i, IL-23i, Janus kinase inhibitors (JAKis) and apremilast classes. Two separate linear mixed models examined trends in weight change before and after treatment initiation with change-point modelling and factors affecting weight over follow-up.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Of 1754 patients, 473 were on NSAIDs or no medications, 571 on csDMARDs, 702 on bDMARDs, 42 on JAKi and 70 on apremilast. Compared with weight at drug initiation, TNFi was associated with a weight gain at one year (1.54\u2009kg, P\u2009&amp;lt;\u20090.01), whereas no significant change was observed with other drug classes. On change-point modelling, a significant decrease in the rate of weight change was observed following IL-17i (slope 0.63\u2009\u00b1\u20090.20 vs \u22120.26\u2009\u00b1\u20090.25, P\u2009&amp;lt;\u20090.01), IL-23i (0.82\u2009\u00b1\u20090.34 vs \u22120.56\u2009\u00b1\u20090.56, P\u2009&amp;lt;\u20090.01) and csDMARDs (0.43\u2009\u00b1\u20090.24 vs \u22120.20\u2009\u00b1\u20090.26, P\u2009&amp;lt;\u20090.01) compared with before treatment initiation. Factors associated with weight gain over follow-up included TNFi, IL12\/23i use, male sex, follow-up duration and higher baseline weight, while with weight loss were apremilast, older age and diabetes mellitus.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The rate of weight gain significantly decreases following the initiation of IL-17i, IL-23i and csDMARDs in PsA. Overall, TNFi and IL12\/23i use is associated with weight gain, while apremilast with weight loss.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/rheumatology\/keaf277","type":"journal-article","created":{"date-parts":[[2025,5,23]],"date-time":"2025-05-23T09:39:23Z","timestamp":1747993163000},"page":"5074-5080","source":"Crossref","is-referenced-by-count":5,"title":["Exploring the impact of conventional and targeted DMARDs on body weight in patients with PsA"],"prefix":"10.1093","volume":"64","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9134-0999","authenticated-orcid":false,"given":"Pankti","family":"Mehta","sequence":"first","affiliation":[{"name":"Gladman Krembil Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network , Toronto, ON,","place":["Canada"]},{"name":"Division of Rheumatology, Department of Medicine, University of Toronto , Toronto, ON,","place":["Canada"]},{"name":"Institute of Medical Science, University of Toronto , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3540-0341","authenticated-orcid":false,"given":"Fadi","family":"Kharouf","sequence":"additional","affiliation":[{"name":"Gladman Krembil Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network , Toronto, ON,","place":["Canada"]},{"name":"Division of Rheumatology, Department of Medicine, University of Toronto , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia Carrizo","family":"Abarza","sequence":"additional","affiliation":[{"name":"Gladman Krembil Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network , Toronto, ON,","place":["Canada"]},{"name":"Division of Rheumatology, Department of Medicine, University of Toronto , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shangyi","family":"Gao","sequence":"additional","affiliation":[{"name":"Gladman Krembil Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1414-4908","authenticated-orcid":false,"given":"Richard J","family":"Cook","sequence":"additional","affiliation":[{"name":"Department of Statistics and Actuarial Science, University of Waterloo , Waterloo, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denis","family":"Poddubnyy","sequence":"additional","affiliation":[{"name":"Gladman Krembil Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network , Toronto, ON,","place":["Canada"]},{"name":"Division of Rheumatology, Department of Medicine, University of Toronto , Toronto, ON,","place":["Canada"]},{"name":"Institute of Medical Science, University of Toronto , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9074-0592","authenticated-orcid":false,"given":"Dafna D","family":"Gladman","sequence":"additional","affiliation":[{"name":"Gladman Krembil Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network , Toronto, ON,","place":["Canada"]},{"name":"Division of Rheumatology, Department of Medicine, University of Toronto , Toronto, ON,","place":["Canada"]},{"name":"Institute of Medical Science, University of Toronto , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinod","family":"Chandran","sequence":"additional","affiliation":[{"name":"Gladman Krembil Psoriatic Arthritis Program, Centre for Prognosis Studies in the Rheumatic Diseases, Schroeder Arthritis Institute, Krembil Research Institute, University Health Network , Toronto, ON,","place":["Canada"]},{"name":"Division of Rheumatology, Department of Medicine, University of Toronto , Toronto, ON,","place":["Canada"]},{"name":"Institute of Medical Science, University of Toronto , Toronto, ON,","place":["Canada"]},{"name":"Department of Laboratory Medicine and Pathobiology, University of Toronto , Toronto, ON,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,5,23]]},"reference":[{"key":"2025090315125178400_keaf277-B1","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1056\/NEJMra1505557","article-title":"Psoriatic arthritis","volume":"376","author":"Ritchlin","year":"2017","journal-title":"N Engl J Med"},{"key":"2025090315125178400_keaf277-B2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1038\/s41584-022-00776-6","article-title":"Psoriatic arthritis from a mechanistic perspective","volume":"18","author":"Schett","year":"2022","journal-title":"Nat Rev Rheumatol"},{"key":"2025090315125178400_keaf277-B3","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1172\/JCI117244","article-title":"Rheumatoid cachexia: cytokine-driven hypermetabolism accompanying reduced body cell mass in chronic inflammation","volume":"93","author":"Roubenoff","year":"1994","journal-title":"J Clin Invest"},{"key":"2025090315125178400_keaf277-B4","first-page":"4113","article-title":"Interleukin 6 reduces lipoprotein lipase activity in adipose tissue of mice in vivo and in 3T3-L1 adipocytes: a possible role for interleukin 6 in cancer cachexia","volume":"52","author":"Greenberg","year":"1992","journal-title":"Cancer Res"},{"key":"2025090315125178400_keaf277-B5","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1111\/j.1346-8138.2008.00525.x","article-title":"Efficacy of infliximab for severe recalcitrant psoriasis after 6 weeks of treatment","volume":"35","author":"de Oliveira","year":"2008","journal-title":"J Dermatol"},{"key":"2025090315125178400_keaf277-B6","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1468-3083.2007.02429.x","article-title":"Anti-tumour necrosis factor-alpha therapy increases body weight in patients with chronic plaque psoriasis: a retrospective cohort study","volume":"22","author":"Gisondi","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025090315125178400_keaf277-B7","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/jdv.12066","article-title":"Evaluation of risk factors for body weight increment in psoriatic patients on infliximab: a multicentre, cross-sectional study","volume":"28","author":"Mah\u00e9","year":"2014","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025090315125178400_keaf277-B8","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.phrs.2008.02.006","article-title":"Effect of anti-tumor necrosis factor-alpha therapies on body mass index in patients with psoriasis","volume":"57","author":"Saraceno","year":"2008","journal-title":"Pharmacol Res"},{"key":"2025090315125178400_keaf277-B9","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1111\/ajd.12044","article-title":"Weight gain and tumour necrosis factor-alpha inhibitors in patients with psoriasis","volume":"54","author":"Tan","year":"2013","journal-title":"Australas J Dermatol"},{"key":"2025090315125178400_keaf277-B10","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1111\/1346-8138.14526","article-title":"Effects of tumor necrosis factor-\u03b1, interleukin-23 and interleukin-17A inhibitors on bodyweight and body mass index in patients with psoriasis","volume":"45","author":"Takamura","year":"2018","journal-title":"J Dermatol"},{"key":"2025090315125178400_keaf277-B11","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1093\/rheumatology\/keab474","article-title":"Effect of the phosphodiesterase 4 inhibitor apremilast on cardiometabolic outcomes in psoriatic disease-results of the Immune Metabolic Associations in Psoriatic Arthritis study","volume":"61","author":"Ferguson","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2025090315125178400_keaf277-B12","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jaad.2019.07.103","article-title":"Change in body weight and body mass index in psoriasis patients receiving biologics: a systematic review and network meta-analysis","volume":"82","author":"Wu","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2025090315125178400_keaf277-B13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1093\/rheumatology\/keq262","article-title":"Observational cohort studies: lessons learnt from the University of Toronto Psoriatic Arthritis Program","volume":"50","author":"Gladman","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"2025090315125178400_keaf277-B14","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","article-title":"Classification criteria for psoriatic arthritis: development of new criteria from a large international study","volume":"54","author":"Taylor","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2025090315125178400_keaf277-B15","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1136\/ard.2009.122259","article-title":"Application of the DAREA\/DAPSA score for assessment of disease activity in psoriatic arthritis","volume":"69","author":"Schoels","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2025090315125178400_keaf277-B16","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1093\/rheumatology\/37.7.760","article-title":"Radiological assessment in psoriatic arthritis","volume":"37","author":"Rahman","year":"1998","journal-title":"Br J Rheumatol"},{"key":"2025090315125178400_keaf277-B17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.lfs.2016.11.033","article-title":"TNF-\u03b1 and cancer cachexia: molecular insights and clinical implications","volume":"170","author":"Patel","year":"2017","journal-title":"Life Sci"},{"key":"2025090315125178400_keaf277-B18","doi-asserted-by":"crossref","first-page":"481","DOI":"10.3389\/fphar.2020.00481","article-title":"Impact of TNF-\u03b1 inhibitors on body weight and BMI: a systematic review and meta-analysis","volume":"11","author":"Patsalos","year":"2020","journal-title":"Front Pharmacol"},{"key":"2025090315125178400_keaf277-B19","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1093\/rheumatology\/ker349","article-title":"Differences in body mass index among individuals with PsA, psoriasis, RA and the general population","volume":"51","author":"Bhole","year":"2012","journal-title":"Rheumatology (Oxford)"},{"key":"2025090315125178400_keaf277-B20","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1111\/j.1468-3083.2012.04571.x","article-title":"Body weight increment in patients treated with infliximab for plaque psoriasis","volume":"27","author":"Florin","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2025090315125178400_keaf277-B21","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1177\/039463200902200124","article-title":"Influence and variation of the body mass index in patients treated with etanercept for plaque-type psoriasis","volume":"22","author":"Esposito","year":"2009","journal-title":"Int J Immunopathol Pharmacol"},{"key":"2025090315125178400_keaf277-B22","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1529-8019.2011.01439.x","article-title":"Prospective assessment of body weight and body composition changes in patients with psoriasis receiving anti-TNF-\u03b1 treatment","volume":"24","author":"Renzo","year":"2011","journal-title":"Dermatol Ther"},{"key":"2025090315125178400_keaf277-B23","author":"Sheane","year":"2013"},{"key":"2025090315125178400_keaf277-B24","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1136\/annrheumdis-2015-207963","article-title":"Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)","volume":"75","author":"Edwards","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2025090315125178400_keaf277-B25","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1476-5381.2009.00194.x","article-title":"The role of the PDE4D cAMP phosphodiesterase in the regulation of glucagon-like peptide-1 release","volume":"157","author":"Ong","year":"2009","journal-title":"Br J Pharmacol"}],"container-title":["Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/rheumatology\/advance-article-pdf\/doi\/10.1093\/rheumatology\/keaf277\/63310353\/keaf277.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/9\/5074\/63310353\/keaf277.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/rheumatology\/article-pdf\/64\/9\/5074\/63310353\/keaf277.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T19:13:04Z","timestamp":1756926784000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/rheumatology\/article\/64\/9\/5074\/8142491"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,23]]},"references-count":25,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,5,23]]},"published-print":{"date-parts":[[2025,9,1]]}},"URL":"https:\/\/doi.org\/10.1093\/rheumatology\/keaf277","relation":{},"ISSN":["1462-0324","1462-0332"],"issn-type":[{"value":"1462-0324","type":"print"},{"value":"1462-0332","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,9]]},"published":{"date-parts":[[2025,5,23]]}}}